224 related articles for article (PubMed ID: 24422231)
1. Implantable melanoma vaccine enters human clinical trials.
Nagda P
Immunotherapy; 2013 Dec; 5(12):1277. PubMed ID: 24422231
[No Abstract] [Full Text] [Related]
2. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
3. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of melanoma: the good news, the bad ones and what to do next.
Marincola FM; Ferrone S
Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156
[No Abstract] [Full Text] [Related]
5. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
6. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
7. New treatments for melanoma.
Demierre MF; Allten S; Brown R
Dermatol Nurs; 2005 Aug; 17(4):287-95. PubMed ID: 16206683
[No Abstract] [Full Text] [Related]
8. Dendritic cell vaccination and immune monitoring.
Aarntzen EH; Figdor CG; Adema GJ; Punt CJ; de Vries IJ
Cancer Immunol Immunother; 2008 Oct; 57(10):1559-68. PubMed ID: 18618110
[TBL] [Abstract][Full Text] [Related]
9. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
10. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD; Snyder A
Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
[TBL] [Abstract][Full Text] [Related]
11. A melanoma vaccine that works? Evidence for a phase III national trial.
Reintgen DS; Shivers SC
Ann Surg Oncol; 1998; 5(7):565-6. PubMed ID: 9831099
[No Abstract] [Full Text] [Related]
12. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
13. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
14. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
[TBL] [Abstract][Full Text] [Related]
15. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
17. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Brolli C; Selva M; Scarpi E; Valmorri L; Nicoletti SV; Guidoboni M; Riccobon A; Ridolfi R
Melanoma Res; 2011 Dec; 21(6):524-9. PubMed ID: 21909041
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
19. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]